Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial
- 27 April 2017
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 76 (8), 1432-1435
- https://doi.org/10.1136/annrheumdis-2016-210647
Abstract
Objectives In the second Computer-Assisted Management in Early Rheumatoid Arthritis trial, patients had started with methotrexate and 10 mg prednisone (MTX+pred) or placebo (MTX+plac). After the trial, prednisone was tapered and stopped, if possible. The objective was to compare, during the post-trial follow-up between the two former strategy groups, initiation of the first biological disease-modifying antirheumatic drug (bDMARD), radiographic outcome and onset of glucocorticoid (GC)-related comorbidities. Methods Data on prednisone and bDMARD use and onset of GC-related comorbidities were collected retrospectively. Sharp/van der Heijde scoring was performed. Data were analysed using Fisher’s exact and Mann-Whitney U tests. Results Of 218 patients post-trial follow-up data were available. The maximum follow-up time was 11.8 years. Fewer patients initiated a first bDMARD in the former MTX+pred compared with the former MTX+plac strategy group: 31% vs 50%, p=0.003. At the 2 year post-trial follow-up, the median erosion score was significantly lower in the former MTX+pred versus former MTX+plac strategy group: 0 (range 0–0) versus 0 (0–2), p=0.002. No significant differences between the former strategy groups in the onset of GC-related comorbidities during the post-trial follow-up were found. Conclusion Addition of 10 mg prednisone daily to an MTX-based treatment strategy in early rheumatoid arthritis results in a lower initiation rate of a first bDMARD and significantly better radiographic outcomes, yet does not result in more GC-related comorbidities.Keywords
This publication has 12 references indexed in Scilit:
- Biologicals in rheumatoid arthritis: current and futureRMD Open, 2015
- Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohortSeminars in Arthritis and Rheumatism, 2015
- Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trialBMJ Open, 2014
- Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximabAnnals Of The Rheumatic Diseases, 2013
- Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid ArthritisAnnals of Internal Medicine, 2012
- Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA studyAnnals Of The Rheumatic Diseases, 2010
- Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2009
- Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysisAnnals Of The Rheumatic Diseases, 2008
- Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse eventsAmerican Journal Of Medicine, 1994
- EFFECTS OF HYDROXYCHLOROQUINE AND SULPHASALAZINE ON PROGRESSION OF JOINT DAMAGE IN RHEUMATOID ARTHRITISThe Lancet, 1989